FDA Announces Efforts to Implement Real-Time Clinical Trial Reporting.

The FDA launched a pilot program for real-time clinical trial reporting, including two proof-of-concept studies: AstraZeneca’s phase II TrAVeRse in treatment-naïve mantle cell lymphoma and Amgen’s phase Ib STREAM-SCLC in limited-stage small cell lung carcinoma.

• Why it matters: Real-time endpoint and data-signal reporting aims to address delays in how trial results are communicated, improving how stakeholders can monitor emerging evidence during studies.
• What they did: The FDA pilot establishes real-time reporting, and it includes two proof-of-concept clinical trials designed to report endpoints and data signals in real time.
• The result: The program enables real-time visibility into trial progress for these specific oncology settings, supporting evaluation of whether such reporting can be implemented in practice.

AI summary of the abstract · may contain errors · not medical advice · read the paper.